Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7015626 | 0.92 | HTT (0.67) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL555962 | 0.89 | HTT (0.74) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL555173 | 0.89 | HTT (0.78) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL13083068 | 0.87 | HTT (0.71) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL16028263 | 0.87 | HPGD (0.62) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL16029542 | 0.86 | ALDH1A1 (0.70) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL556115 | 0.86 | HTT (0.70) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL556785 | 0.85 | ALDH1A1 (0.75) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL555429 | 0.85 | HTT (0.68) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL555988 | 0.83 | HTT (0.70) | HTTSMN1; SMN2CYP1A2CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2970316-B1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-11-08 | — | — | EP | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-05-26 | — | — | US | disclosed |
| WO-2014152287-A9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014152287-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145257-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | HTT 1025/4885SMN1; SMN2 1307/4885CYP1A2 2502/4885 |
| US-20140275528-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | HTT 1025/4885SMN1; SMN2 1307/4885CYP1A2 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.